{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T18:44:04Z","timestamp":1792089844256,"version":"4.4.0"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T00:00:00Z","timestamp":1718668800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1007\/s40257-024-00869-w","type":"journal-article","created":{"date-parts":[[2024,6,18]],"date-time":"2024-06-18T03:03:26Z","timestamp":1718679806000},"page":"639-654","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":58,"title":["Integrated Safety Update of Abrocitinib in 3802 Patients with Moderate-to-Severe Atopic Dermatitis: Data from More than 5200 Patient-Years with Up to 4 Years of Exposure"],"prefix":"10.1007","volume":"25","author":[{"given":"Eric L.","family":"Simpson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan I.","family":"Silverberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Audrey","family":"Nosbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Winthrop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Guttman-Yassky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin M.","family":"Hoffmeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Egeberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hernan","family":"Valdez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyun","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saleem A.","family":"Farooqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3006-1675","authenticated-orcid":false,"given":"Justine","family":"Alderfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanti","family":"Chittuluru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,18]]},"reference":[{"key":"869_CR1","unstructured":"Cibinqo 100 mg film-coated tablets. Summary of product characteristics. Kent: Pfizer, Limited; 2021. Updated March 10, 2023."},{"key":"869_CR2","unstructured":"European Medicines Agency. Cibinqo\u00ae (abrocitinib). Summary of product characteristics. Pfizer Europe MA EEIG; 2024."},{"key":"869_CR3","unstructured":"Cibinqo (abrocitinib) tablets, for oral use. Prescribing information. New York (NY): Pfizer Inc.; 2023."},{"issue":"12","key":"869_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1001\/jamadermatol.2019.2855","volume":"155","author":"MJ Gooderham","year":"2019","unstructured":"Gooderham MJ, Forman SB, Bissonnette R, Beebe JS, Zhang W, Banfield C, et al. Efficacy and safety of oral Janus kinase 1 inhibitor abrocitinib for patients with atopic dermatitis: a phase 2 randomized clinical trial. JAMA Dermatol. 2019;155(12):1371\u20139. https:\/\/doi.org\/10.1001\/jamadermatol.2019.2855.","journal-title":"JAMA Dermatol"},{"issue":"8","key":"869_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1001\/jamadermatol.2020.1406","volume":"156","author":"JI Silverberg","year":"2020","unstructured":"Silverberg JI, Simpson EL, Thyssen JP, Gooderham M, Chan G, Feeney C, et al. Efficacy and safety of abrocitinib in patients with moderate-to-severe atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156(8):863\u201373. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1406.","journal-title":"JAMA Dermatol"},{"issue":"10246","key":"869_CR6","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/s0140-6736(20)30732-7","volume":"396","author":"EL Simpson","year":"2020","unstructured":"Simpson EL, Sinclair R, Forman S, Wollenberg A, Aschoff R, Cork M, et al. Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2020;396(10246):255\u201366. https:\/\/doi.org\/10.1016\/s0140-6736(20)30732-7.","journal-title":"Lancet"},{"issue":"1","key":"869_CR7","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.jaad.2021.05.075","volume":"86","author":"A Blauvelt","year":"2022","unstructured":"Blauvelt A, Silverberg JI, Lynde CW, Bieber T, Eisman S, Zdybski J, et al. Abrocitinib induction, randomized withdrawal, and retreatment in patients with moderate-to-severe atopic dermatitis: results from the JAK1 Atopic Dermatitis Efficacy and Safety (JADE) REGIMEN phase 3 trial. J Am Acad Dermatol. 2022;86(1):104\u201312. https:\/\/doi.org\/10.1016\/j.jaad.2021.05.075.","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"869_CR8","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","volume":"384","author":"T Bieber","year":"2021","unstructured":"Bieber T, Simpson EL, Silverberg JI, Tha\u00e7i D, Paul C, Pink AE, et al. Abrocitinib versus placebo or dupilumab for atopic dermatitis. N Engl J Med. 2021;384(12):1101\u201312. https:\/\/doi.org\/10.1056\/NEJMoa2019380.","journal-title":"N Engl J Med"},{"issue":"10","key":"869_CR9","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1001\/jamadermatol.2021.2830","volume":"157","author":"LF Eichenfield","year":"2021","unstructured":"Eichenfield LF, Flohr C, Sidbury R, Siegfried E, Szalai Z, Galus R, et al. Efficacy and safety of abrocitinib in combination with topical therapy in adolescents with moderate-to-severe atopic dermatitis: the JADE TEEN randomized clinical trial. JAMA Dermatol. 2021;157(10):1165\u201373. https:\/\/doi.org\/10.1001\/jamadermatol.2021.2830.","journal-title":"JAMA Dermatol"},{"issue":"5","key":"869_CR10","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1007\/s40257-021-00618-3","volume":"22","author":"EL Simpson","year":"2021","unstructured":"Simpson EL, Silverberg JI, Nosbaum A, Winthrop KL, Guttman-Yassky E, Hoffmeister KM, et al. Integrated safety analysis of abrocitinib for the treatment of moderate-to-severe atopic dermatitis from the phase II and phase III clinical trial program. Am J Clin Dermatol. 2021;22(5):693\u2013707. https:\/\/doi.org\/10.1007\/s40257-021-00618-3.","journal-title":"Am J Clin Dermatol"},{"key":"869_CR11","unstructured":"Cork MJ, Deleuran M, Geng B, Silverberg JI, Simpson EL, Stein Gold LF, et al. Abrocitinib treatment in patients with moderate-to-severe atopic dermatitis: safety of abrocitinib stratified by age. In: European Academy of Dermatology and Venereology (EADV) 30th Congress; 29 Sep\u20132 Oct 2021; Berlin."},{"issue":"10348","key":"869_CR12","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/s0140-6736(22)01199-0","volume":"400","author":"K Reich","year":"2022","unstructured":"Reich K, Thyssen JP, Blauvelt A, Eyerich K, Soong W, Rice ZP, et al. Efficacy and safety of abrocitinib versus dupilumab in adults with moderate-to-severe atopic dermatitis: a randomised, double-blind, multicentre phase 3 trial. Lancet. 2022;400(10348):273\u201382. https:\/\/doi.org\/10.1016\/s0140-6736(22)01199-0.","journal-title":"Lancet"},{"issue":"15","key":"869_CR13","doi-asserted-by":"publisher","first-page":"458","DOI":"10.15585\/mmwr.mm6915e3","volume":"69","author":"S Garg","year":"2020","unstructured":"Garg S, Kim L, Whitaker M, O\u2019Halloran A, Cummings C, Holstein R, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019\u2014COVID-NET, 14 States, March 1\u201330, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458\u201364. https:\/\/doi.org\/10.15585\/mmwr.mm6915e3.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"869_CR14","doi-asserted-by":"publisher","unstructured":"Sunzini F, McInnes I, Siebert S. JAK inhibitors and infections risk: focus on herpes zoster. Ther Adv Musculoskelet Dis. 2020;12:1759720X20936059. https:\/\/doi.org\/10.1177\/1759720X20936059.","DOI":"10.1177\/1759720X20936059"},{"issue":"6","key":"869_CR15","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1093\/ije\/dyz129","volume":"48","author":"F Ghilotti","year":"2019","unstructured":"Ghilotti F, Bellocco R, Ye W, Adami HO, Trolle LY. Obesity and risk of infections: results from men and women in the Swedish National March Cohort. Int J Epidemiol. 2019;48(6):1783\u201394. https:\/\/doi.org\/10.1093\/ije\/dyz129.","journal-title":"Int J Epidemiol"},{"issue":"11","key":"869_CR16","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/aje\/kwv300","volume":"183","author":"MC Harps\u00f8e","year":"2016","unstructured":"Harps\u00f8e MC, Nielsen NM, Friis-M\u00f8ller N, Andersson M, Wohlfahrt J, Linneberg A, et al. Body mass index and risk of infections among women in the Danish national birth cohort. Am J Epidemiol. 2016;183(11):1008\u201317. https:\/\/doi.org\/10.1093\/aje\/kwv300.","journal-title":"Am J Epidemiol"},{"issue":"10","key":"869_CR17","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1111\/obr.12055","volume":"14","author":"DT Phung","year":"2013","unstructured":"Phung DT, Wang Z, Rutherford S, Huang C, Chu C. Body mass index and risk of pneumonia: a systematic review and meta-analysis. Obes Rev. 2013;14(10):839\u201357. https:\/\/doi.org\/10.1111\/obr.12055.","journal-title":"Obes Rev"},{"issue":"4","key":"869_CR18","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/bjd.20887","volume":"186","author":"J Wan","year":"2022","unstructured":"Wan J, Shin DB, Syed MN, Abuabara K, Lemeshow AR, Gelfand JM. Risk of herpesvirus, serious and opportunistic infections in atopic dermatitis: a population-based cohort study. Br J Dermatol. 2022;186(4):664\u201372. https:\/\/doi.org\/10.1111\/bjd.20887.","journal-title":"Br J Dermatol"},{"key":"869_CR19","doi-asserted-by":"publisher","unstructured":"Clarke B, Yates M, Adas M, Bechman K, Galloway J. The safety of JAK-1 inhibitors. Rheumatology (Oxford). 2021;60(Suppl. 2):ii24\u2013ii30. https:\/\/doi.org\/10.1093\/rheumatology\/keaa895.","DOI":"10.1093\/rheumatology\/keaa895"},{"issue":"6","key":"869_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2014-004833","volume":"4","author":"K Kawai","year":"2014","unstructured":"Kawai K, Gebremeskel BG, Acosta CJ. Systematic review of incidence and complications of herpes zoster: towards a global perspective. BMJ Open. 2014;4(6): e004833. https:\/\/doi.org\/10.1136\/bmjopen-2014-004833.","journal-title":"BMJ Open"},{"issue":"2","key":"869_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1067\/s0190-9622(03)00896-x","volume":"49","author":"A Wollenberg","year":"2003","unstructured":"Wollenberg A, Zoch C, Wetzel S, Plewig G, Przybilla B. Predisposing factors and clinical features of eczema herpeticum: a retrospective analysis of 100 cases. J Am Acad Dermatol. 2003;49(2):198\u2013205. https:\/\/doi.org\/10.1067\/s0190-9622(03)00896-x.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"869_CR22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s12016-019-08768-3","volume":"59","author":"A Damour","year":"2020","unstructured":"Damour A, Garcia M, Seneschal J, L\u00e9v\u00eaque N, Bodet C. Eczema herpeticum: clinical and pathophysiological aspects. Clin Rev Allergy Immunol. 2020;59(1):1\u201318. https:\/\/doi.org\/10.1007\/s12016-019-08768-3.","journal-title":"Clin Rev Allergy Immunol"},{"issue":"6","key":"869_CR23","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1016\/j.jaci.2015.06.047","volume":"136","author":"L Gao","year":"2015","unstructured":"Gao L, Bin L, Rafaels NM, Huang L, Potee J, Ruczinski I, et al. Targeted deep sequencing identifies rare loss-of-function variants in IFNGR1 for risk of atopic dermatitis complicated by eczema herpeticum. J Allergy Clin Immunol. 2015;136(6):1591\u2013600. https:\/\/doi.org\/10.1016\/j.jaci.2015.06.047.","journal-title":"J Allergy Clin Immunol"},{"key":"869_CR24","doi-asserted-by":"publisher","unstructured":"Leung DY, Gao PS, Grigoryev DN, Rafaels NM, Streib JE, Howell MD, et al. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-\u03b3 response. J Allergy Clin Immunol. 2011;127(4):965\u201373.e1\u20135. https:\/\/doi.org\/10.1016\/j.jaci.2011.02.010.","DOI":"10.1016\/j.jaci.2011.02.010"},{"issue":"10","key":"869_CR25","doi-asserted-by":"publisher","first-page":"3500","DOI":"10.1016\/j.jaip.2020.07.018","volume":"8","author":"B Ungar","year":"2020","unstructured":"Ungar B, Pavel AB, Robson PM, Kaufman A, Pruzan A, Brunner P, et al. A preliminary (18)F-FDG-PET\/MRI study shows increased vascular inflammation in moderate-to-severe atopic dermatitis. J Allergy Clin Immunol Pract. 2020;8(10):3500\u20136. https:\/\/doi.org\/10.1016\/j.jaip.2020.07.018.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"869_CR26","doi-asserted-by":"publisher","first-page":"1821","DOI":"10.1016\/j.jaci.2018.11.030","volume":"143","author":"A Ascott","year":"2019","unstructured":"Ascott A, Mulick A, Yu AM, Prieto-Merino D, Schmidt M, Abuabara K, et al. Atopic eczema and major cardiovascular outcomes: a systematic review and meta-analysis of population-based studies. J Allergy Clin Immunol. 2019;143(5):1821\u20139. https:\/\/doi.org\/10.1016\/j.jaci.2018.11.030.","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"869_CR27","doi-asserted-by":"publisher","first-page":"1074","DOI":"10.1016\/j.jid.2016.11.031","volume":"137","author":"M Standl","year":"2017","unstructured":"Standl M, Tesch F, Baurecht H, Rodriguez E, Muller-Nurasyid M, Gieger C, et al. Association of atopic dermatitis with cardiovascular risk factors and diseases. J Invest Dermatol. 2017;137(5):1074\u201381. https:\/\/doi.org\/10.1016\/j.jid.2016.11.031.","journal-title":"J Invest Dermatol"},{"key":"869_CR28","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.k1786","volume":"361","author":"RJ Silverwood","year":"2018","unstructured":"Silverwood RJ, Forbes HJ, Abuabara K, Ascott A, Schmidt M, Schmidt SAJ, et al. Severe and predominantly active atopic eczema in adulthood and long term risk of cardiovascular disease: population based cohort study. BMJ. 2018;361: k1786. https:\/\/doi.org\/10.1136\/bmj.k1786.","journal-title":"BMJ"},{"issue":"11","key":"869_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0277469","volume":"17","author":"MM Hedderson","year":"2022","unstructured":"Hedderson MM, Asgari MM, Xu F, Quesenberry CP, Sridhar S, Geier J, et al. Rates of cardiovascular events among patients with moderate-to-severe atopic dermatitis in an integrated health care system: a retrospective cohort study. PLoS ONE. 2022;17(11):e0277469. https:\/\/doi.org\/10.1371\/journal.pone.0277469.","journal-title":"PLoS ONE"},{"issue":"1","key":"869_CR30","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/j.jaci.2016.01.015","volume":"138","author":"YMF Andersen","year":"2016","unstructured":"Andersen YMF, Egeberg A, Gislason GH, Hansen PR, Skov L, Thyssen JP. Risk of myocardial infarction, ischemic stroke, and cardiovascular death in patients with atopic dermatitis. J Allergy Clin Immunol. 2016;138(1):310-2.e3. https:\/\/doi.org\/10.1016\/j.jaci.2016.01.015.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"869_CR31","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1056\/NEJMoa2109927","volume":"386","author":"SR Ytterberg","year":"2022","unstructured":"Ytterberg SR, Bhatt DL, Mikuls TR, Koch GG, Fleischmann R, Rivas JL, et al. Cardiovascular and cancer risk with tofacitinib in rheumatoid arthritis. N Engl J Med. 2022;386(4):316\u201326. https:\/\/doi.org\/10.1056\/NEJMoa2109927.","journal-title":"N Engl J Med"},{"issue":"9","key":"869_CR32","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.1136\/annrheumdis-2011-200726","volume":"71","author":"JA Avina-Zubieta","year":"2012","unstructured":"Avina-Zubieta JA, Thomas J, Sadatsafavi M, Lehman AJ, Lacaille D. Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies. Ann Rheum Dis. 2012;71(9):1524\u20139. https:\/\/doi.org\/10.1136\/annrheumdis-2011-200726.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"869_CR33","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1080\/03007995.2022.2088715","volume":"38","author":"ME Montez-Rath","year":"2022","unstructured":"Montez-Rath ME, Lubwama R, Kapphahn K, Ling AY, LoCasale R, Robinson L, et al. Characterizing real world safety profile of oral Janus kinase inhibitors among adult atopic dermatitis patients: evidence transporting from the rheumatoid arthritis population. Curr Med Res Opin. 2022;38(8):1431\u20137. https:\/\/doi.org\/10.1080\/03007995.2022.2088715.","journal-title":"Curr Med Res Opin"},{"issue":"9","key":"869_CR34","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archderm.141.9.1123","volume":"141","author":"L Hagstr\u00f6mer","year":"2005","unstructured":"Hagstr\u00f6mer L, Ye W, Nyr\u00e9n O, Emtestam L. Incidence of cancer among patients with atopic dermatitis. Arch Dermatol. 2005;141(9):1123\u20137. https:\/\/doi.org\/10.1001\/archderm.141.9.1123.","journal-title":"Arch Dermatol"},{"issue":"3","key":"869_CR35","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1111\/j.0022-202X.2005.23839.x","volume":"125","author":"AB Olesen","year":"2005","unstructured":"Olesen AB, Engholm G, Storm HH, Thestrup-Pedersen K. The risk of cancer among patients previously hospitalized for atopic dermatitis. J Invest Dermatol. 2005;125(3):445\u20139. https:\/\/doi.org\/10.1111\/j.0022-202X.2005.23839.x.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"869_CR36","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.immuni.2019.06.025","volume":"51","author":"FR Greten","year":"2019","unstructured":"Greten FR, Grivennikov SI. Inflammation and cancer: triggers, mechanisms, and consequences. Immunity. 2019;51(1):27\u201341. https:\/\/doi.org\/10.1016\/j.immuni.2019.06.025.","journal-title":"Immunity"},{"issue":"2","key":"869_CR37","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1001\/jamadermatol.2019.3786","volume":"156","author":"L Wang","year":"2020","unstructured":"Wang L, Bierbrier R, Drucker AM, Chan AW. Noncutaneous and cutaneous cancer risk in patients with atopic dermatitis: a systematic review and meta-analysis. JAMA Dermatol. 2020;156(2):158\u201371. https:\/\/doi.org\/10.1001\/jamadermatol.2019.3786.","journal-title":"JAMA Dermatol"},{"issue":"9","key":"869_CR38","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.2340\/00015555-2703","volume":"97","author":"S Ruff","year":"2017","unstructured":"Ruff S, Egeberg A, Andersen YMF, Gislason G, Skov L, Thyssen JP. Prevalence of cancer in adult patients with atopic dermatitis: a nationwide study. Acta Derm Venereol. 2017;97(9):1127\u20139. https:\/\/doi.org\/10.2340\/00015555-2703.","journal-title":"Acta Derm Venereol"},{"issue":"10","key":"869_CR39","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1001\/jamadermatol.2020.1948","volume":"156","author":"KE Mansfield","year":"2020","unstructured":"Mansfield KE, Schmidt SAJ, Darvalics B, Mulick A, Abuabara K, Wong AYS, et al. Association between atopic eczema and cancer in England and Denmark. JAMA Dermatol. 2020;156(10):1086\u201397. https:\/\/doi.org\/10.1001\/jamadermatol.2020.1948.","journal-title":"JAMA Dermatol"},{"key":"869_CR40","doi-asserted-by":"publisher","unstructured":"Arana A, Wentworth CE, Fern\u00e1ndez-Vidaurre C, Schlienger RG, Conde E, Arellano FM. Incidence of cancer in the general population and in patients with or without atopic dermatitis in the U.K. Br J Dermatol. 2010;163(5):1036\u201343. https:\/\/doi.org\/10.1111\/j.1365-2133.2010.09887.x.","DOI":"10.1111\/j.1365-2133.2010.09887.x"},{"issue":"3","key":"869_CR41","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-071172","volume":"13","author":"MM Hedderson","year":"2023","unstructured":"Hedderson MM, Asgari MM, Xu F, Quesenberry CP, Sridhar S, Geier J, et al. Rates of malignancies among patients with moderate to severe atopic dermatitis: a retrospective cohort study. BMJ Open. 2023;13(3): e071172. https:\/\/doi.org\/10.1136\/bmjopen-2022-071172.","journal-title":"BMJ Open"},{"issue":"8","key":"869_CR42","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1001\/archdermatol.2012.1374","volume":"148","author":"J Leonardi-Bee","year":"2012","unstructured":"Leonardi-Bee J, Ellison T, Bath-Hextall F. Smoking and the risk of nonmelanoma skin cancer: systematic review and meta-analysis. Arch Dermatol. 2012;148(8):939\u201346. https:\/\/doi.org\/10.1001\/archdermatol.2012.1374.","journal-title":"Arch Dermatol"},{"issue":"2","key":"869_CR43","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s10552-011-9872-y","volume":"23","author":"DE Rollison","year":"2012","unstructured":"Rollison DE, Iannacone MR, Messina JL, Glass LF, Giuliano AR, Roetzheim RG, et al. Case-control study of smoking and non-melanoma skin cancer. Cancer Causes Control. 2012;23(2):245\u201354. https:\/\/doi.org\/10.1007\/s10552-011-9872-y.","journal-title":"Cancer Causes Control"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00869-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00869-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00869-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T05:20:47Z","timestamp":1719033647000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00869-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,18]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["869"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00869-w","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,18]]},"assertion":[{"value":"1 May 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Pfizer, Inc. The open access fee was funded by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Eric L. Simpson has received grants from Pfizer Inc., Eli Lilly and Company, Kyowa Kirin, LEO Pharma, Merck, and Regeneron Pharmaceuticals, and personal fees from Pfizer Inc., Bausch Health (Valeant), Dermira, Eli Lilly and Company, Galderma, LEO Pharma, Menlo Therapeutics, Novartis, Regeneron Pharmaceuticals, and Sanofi Genzyme. Jonathan I. Silverberg served as an investigator for Celgene, Eli Lilly and Company, F. Hoffmann-La Roche, Menlo Therapeutics, Realm Therapeutics, Regeneron Pharmaceuticals, and Sanofi Genzyme; as a consultant for Pfizer Inc., AbbVie, Anacor, AnaptysBio, Arena Pharmaceuticals, Dermavant, Dermira, Eli Lilly and Company, Galderma, GlaxoSmithKline, Glenmark, Incyte, Kiniksa Pharmaceuticals, LEO Pharma, Menlo Therapeutics, Novartis, Realm Therapeutics, Regeneron Pharmaceuticals, and Sanofi Genzyme; and as a speaker for Regeneron Pharmaceuticals and Sanofi Genzyme. Audrey Nosbaum is a consultant for Pfizer Inc., AbbVie, Eli Lilly and Company, Galderma, LEO Pharma, Novartis, and Sanofi Genzyme; a speaker for AbbVie, Regeneron Pharmaceuticals, and Sanofi Genzyme; an investigator for AbbVie, Eli Lilly and Company, Incyte, LEO Pharma, Novartis, and Sanofi Genzyme; and is on advisory boards for Pfizer Inc., AbbVie, LEO Pharma, and Sanofi Genzyme. Kevin Winthrop reports research grants from Pfizer Inc. and Bristol Myers Squibb, and consulting fees from Pfizer Inc., AbbVie, AstraZeneca, Bristol Myers Squibb, Eli Lilly and Company, Galapagos, Gilead, GlaxoSmithKline, Novartis, Regeneron Pharmaceuticals, Roche, and Union Chimique Belge (UCB). Emma Guttman-Yassky has served as an advisory board member for Pfizer Inc., Asana BioSciences (honorarium), Celgene, Dermira, Galderma, Glenmark, MedImmune, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Stiefel\/GlaxoSmithKline, and Vitae; a consultant for Pfizer Inc., AbbVie, Almirall (honorarium), Anacor, Asana BioSciences, Celgene, Dermira, Eli Lilly and Company, Galderma, Glenmark, Kiowa Kirin, LEO Pharma, MedImmune, Mitsubishi Tanabe, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Stiefel\/GlaxoSmithKline, and Vitae; and an investigator for Celgene, Eli Lilly and Company (grants to institution), LEO Pharma, MedImmune, and Regeneron Pharmaceuticals. Karin M. Hoffmeister has no disclosures to report. Alexander Egeberg has received research funding from Pfizer Inc., AbbVie, Almirall, Bristol Myers Squibb, Boehringer Ingelheim, Eli Lilly and Company, Novartis, Janssen, the Danish National Psoriasis Foundation, the Simon Spies Foundation, and the Kongelig Hofbuntmager Aage Bangs Foundation; and honoraria as consultant and\/or speaker from Pfizer Inc., AbbVie, Amgen, Almirall, Bristol Myers Squibb, Boehringer Ingelheim, Dermavant, Eli Lilly and Company, Gal\u00e1pagos NV, Galderma, Horizon Therapeutics, Janssen, LEO Pharma, McNeil Consumer Healthcare, Mylan, Novartis, Samsung Bioepis Co., Ltd., Sun Pharmaceutical, UCB, UNION Therapeutics, and Zuellig Pharma Ltd. He is a current employee of LEO Pharma. Hernan Valdez, Haiyun Fan, Saleem A. Farooqui, Gary Chan, Justine Alderfer, William Romero, and Kanti Chittuluru are employees and shareholders of Pfizer Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All study documents and procedures were approved by the appropriate institutional review boards\/ethics committees at each study site. The studies were conducted in compliance with the ethical principles from the Declaration of Helsinki and all International Council for Harmonisation Good Clinical Practice Guidelines. All local regulatory requirements were followed.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants of the individual studies included in this updated integrated safety analysis.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Upon request, and subject to review, Pfizer will provide the data that support the findings of this study. Subject to certain criteria, conditions, and exceptions, Pfizer may also provide access to the related individual de-identified participant data. See\n                      \n                      for more information.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"ELS, JIS, AN, KW, EGY, KMH, AE, HV, SAF, GC, JA, WR, and KC contributed to the conceptualization and design of the analysis. HF performed or supported the data analysis. All authors interpreted the data, provided critical feedback on the manuscript, approved the final manuscript for submission, and are accountable for the accuracy and integrity of the article.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}